1. Healthcare

  2. •

    Medical - Distribution
Public Joint-Stock Company PROTEK

Public Joint-Stock Company PROTEK

PRTK.ME
Public Joint-Stock Company PROTEKRU flagMoscow Stock Exchange
99.60
RUB
- -
- -
44.20BMarket Cap
Public Joint-Stock Company PROTEK
PRTK.ME
(Moscow Stock Exchange)

Recent

price

99.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
FRC
158.16
193.79
198.91
198.06
203.08
238.72
265.08
304.43
391.39
470.08
490.29
477.32
513.43
Revenue per Share
1.37
1.05
7.09
1.83
3.5
5.28
3.73
9.16
21.75
11.53
10.71
11.73
6.73
Basic EPS, GAAP
0.89
6.56
11.24
-0.34
1.46
9.2
2.85
6.8
26.25
17.62
8.55
51.26
23.04
Free Cash Flow per Basic Share
0.23
0.01
1.87
0.02
0.03
1.79
6.03
1.88
- -
19.59
10.08
- -
- -
Dividend per Share
24.6
25.34
27.48
26.76
29.09
32.65
30.36
38.24
61.25
48.51
52.31
64.04
72
Book Value per Share
15.43
14.51
17.94
28.24
26.83
30.64
28.48
35.04
55.33
46.11
43.94
54.71
60.83
Tangible Book Value per Share
400
400
460
504
527
526
526
516
499
514
527
527
517
Basic Weighted Avg Shares
63,265
77,514
91,581
99,841
107,053
125,502
139,311
156,948
195,309
241,482
258,455
251,733
265,647
Sales/Revenue/Turnover
2.31
3.43
5.51
1.43
2.01
2.62
2.39
2.73
4.59
3.84
3.21
3.19
3.16
Operating Margin (%)
660
821
786
786
827
865
862
828
917
1,097
1,475
1,796
5,108
Depreciation Expense
549
418
3,262
922
1,847
2,774
1,962
4,722
10,854
5,922
5,646
6,185
3,481
Net Income, GAAP
46.72
44.94
23.46
32.17
20.84
21.65
23.68
17.53
20.17
22.5
23.31
20.7
24.83
Effective Tax Rate (%)
0.87
0.54
3.56
0.92
1.73
2.21
1.41
3.01
5.56
2.45
2.18
2.46
1.31
Profit Margin (%)
2,956
-1,431
729
6,405
6,631
9,084
7,712
10,669
19,416
11,310
7,529
11,622
6,212
Working Capital
6,493
3,092
32
18
14
2
1
9
2
- -
2,729
2,042
20,866
LT Debt
9,849
10,226
12,767
19,346
21,212
23,057
21,811
24,907
34,530
31,057
33,774
39,940
42,118
Total Equity
- -
7.63
22.7
5.46
8.26
11.43
11.15
14.57
23.2
21.2
17.46
15.03
11.09
Return on Invested Capital (%)
- -
4.88
22.63
7.1
12.48
16.7
11.44
25.7
41.88
20.36
19.24
17.76
10.9
Return on Capital (%)
- -
4.19
28.63
7.06
12.81
17.07
11.84
26.47
43.17
21.35
21.51
20.16
9.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.97%
12.21%
5.45%
Free Cash Flow
58.04%
127.29%
-55.91%
Net Income, GAAP
23.57%
9.12%
-43.72%
Sales/Revenue/Turnover
11.52%
11.61%
5.53%
Total Cash Common Dividend
- -
- -
-100%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
251,733
2019
- -
- -
- -
- -
265,647
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
11.73
2019
- -
- -
- -
- -
6.73
2020
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
Similar Companies
Alfresa Holdings Corporation (ARHCF)
Medela Potentia Tbk. (MDLA.JK)
Clinigen Group plc (CLIN.L)
XIN JIANG READY HEALTH INDUSTRY Co., Ltd. (600090.SS)
160 Health International Ltd. (2656.HK)
IVD Medical Holding Limited (1931.HK)
Business
Public Joint-Stock Company PROTEK (PRTK.ME), a subsidiary of LLC PROTEK, operates as a vertically integrated pharmaceutical holding company in Russia, founded in 1990 and headquartered in Moscow. The company engages in pharmaceutical distribution, retail pharmacy operations, and drug production through three main segments; the Distribution segment supplies pharmaceuticals, health, and beauty products to medical facilities, independent pharmacies, pharmacy chains, and wholesalers, while offering ePharma2 inventory automation software, contract manufacturing for medicines, bandages, and napkins, plus customs and warehouse services; the Retail segment sells these products via the Rigla pharmacy chain; and the Production segment manufactures medicines for cardiology, rheumatology, neurology, oncology, nephrology, and general use, including recombinant human erythropoietin for anemia treatment, alongside raw material distribution and financial intermediation. It primarily serves the Russian market with some international subsidiaries in Ukraine, the Virgin Islands, and Cyprus, targeting pharmacies, healthcare providers, and end consumers through production facilities like FarmFirma Soteks ZAO, Protek-SVM OOO, and Proteinovyi Kontur OOO. Recent developments include reclaiming the top position as Russia's leading drug supplier in Q1 2023 via active public procurement participation; constructing a new 1.3 billion ruble warehouse in the Moscow region in 2023 to bolster storage capacity; pursuing recovery of over 500 million rubles from the bankruptcy of partner Godovalov LLC in 2024, part of losses exceeding 1 billion rubles; cautiously managing shipments amid regional pharmacy chain bankruptcy risks; and changing status from public joint-stock to privately held company.